Compare YDES & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YDES | WVE |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | Taiwan | Singapore |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | 2015 |
| Metric | YDES | WVE |
|---|---|---|
| Price | $11.97 | $16.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $25.93 |
| AVG Volume (30 Days) | 110.9K | ★ 12.7M |
| Earning Date | 09-30-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $510,360.00 | ★ $109,230,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $31.09 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 45.76 | ★ 103.75 |
| 52 Week Low | $5.30 | $5.28 |
| 52 Week High | $31.00 | $21.73 |
| Indicator | YDES | WVE |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 68.44 |
| Support Level | N/A | $6.93 |
| Resistance Level | N/A | $21.73 |
| Average True Range (ATR) | 0.00 | 1.40 |
| MACD | 0.00 | 1.38 |
| Stochastic Oscillator | 0.00 | 66.75 |
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.